Sage Therapeutics (NASDAQ:SAGE) Stock, Quote.Headers.trade-ideas

Sage Therapeutics

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.

Rivian R3

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

EVGO

HYLN

PAHC

RIVN

SAGE

Rivian Automotive Cuts Production Outlook, Joins EVgo And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

Biotech

Earnings

Earnings Beats

Large Cap

Mid Cap

Penny Stocks

Small Cap

Analyst Ratings

General

BIIB

FULC

KRYS

Sage Therapeutics, Inc. (NASDAQ: SAGE) announced that partner Biogen (NASDAQ: BIIB) has terminated its rights related to the investigational neurology candidate, SAGE-324.

SAGE, BIIB End Collaboration for Neurology Candidate SAGE-324

Health Care

Contracts

Biogen Terminates Collaboration With Sage Therapeutics For Neurological Disorder Candidate

Sage Therapeutics Inc

SAGE GROUP ORD

SAGEN MI CDA INC PFD A by SAGEN MI CDA INC.

Sage Gold Inc

Sage Group (The) PLC

SAGE GROUP UNSP/ADR by Sage Group plc (The)

Sage Potash Corp

WIIM

Sage Therapeutics shares are trading lower after RBC Capital downgraded the stock from Sector Perform to Underperform and cut its price target from $10 to $4.

Ratings for Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) were provided by 13 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Sage Therapeutics and provided 12-month price targets. The average target is $17.38, accompanied by a high estimate of $52.00 and a low estimate of $4.00. This current average represents a 21.53% decrease from the previous average price target of $22.15. 
<img src="https://www.benzinga.com/files/images/story/2024/1728057652_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Sage Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$4.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$13.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Yasmeen Rahimi</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$52.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$23.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sage Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Sage Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Sage Therapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sage Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Sage Therapeutics: A Closer Look</h2>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Breaking Down Sage Therapeutics's Financial Performance</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Sage Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 249.8%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Sage Therapeutics's net margin excels beyond industry benchmarks, reaching -1188.51%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Sage Therapeutics's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -15.42%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -14.04%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.0.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: Sage Therapeutics In The Eyes Of 13 Experts

RBC Capital analyst Brian Abrahams downgrades Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Sector Perform to Underperform and lowers the price target from $10 to $4.

Downgrades

Price Target

RBC Capital Downgrades Sage Therapeutics to Underperform, Lowers Price Target to $4

U.S. stock futures were higher this morning, with the Dow futures gaining over 50 points on Friday.
Shares of Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) fell sharply in today's pre-market trading after the company lowered its annual production guidance due to supply shortage of shared component on the <a href="https://www.benzinga.com/markets/equities/24/10/41182921/rivians-production-forecast-hits-bump-supply-shortage-sends-shares-tumbling">R1 and RCV platforms</a>.
The company produced 13,157 vehicles at its manufacturing facility in Normal, Illinois, and delivered 10,018 cars during the same period. Rivian is experiencing a supply shortage that began in the third quarter of this year and has intensified in recent weeks.
Rivian Automotive shares dipped 6.8% to $10.05 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Sage Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares declined 11.3% to $6.20 in pre-market trading.</li>
<li>ZIM Integrated Shipping Services Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZIM#NYSE">ZIM</a>) shares dipped 7% to $20.17 in pre-market trading after falling around 7% on Thursday.</li>
<li>Hyliion Holdings Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYLN#NYSE">HYLN</a>) shares fell 5.7% to $2.3290 in pre-market trading. Hyliion recently announced its KARNO linear generator now qualifies under California&#8217;s renewables portfolio standard.</li>
<li>Phibro Animal Health Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAHC#NASDAQ">PAHC</a>) shares fell 5.4% to $20.00 in pre-market trading,</li>
<li>AMTD Digital Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HKD#NYSE">HKD</a>) shares fell 5.2% to $4.95 in pre-market trading after jumping over 33% on Thursday.</li>
<li>EVgo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGO#NASDAQ">EVGO</a>) shares declined 4.4% to $6.04 in pre-market trading. EVgo shares jumped more than 60% on Thursday after the company announced it received a $1.05 billion conditional commitment for a Department of Energy (DOE) loan guarantee to accelerate the buildout of public fast charging across the US.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41180069/dow-tumbles-nearly-200-points-amid-growing-middle-east-concerns-investor-optimism-declines-fear-ind">Dow Tumbles Nearly 200 Points Amid Growing Middle East Concerns: Investor Optimism Declines, Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

Rivian Automotive Cuts Production Outlook, Joins EVgo And Other Big Stocks Moving Lower In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares moved upwards by 16.4% to $3.72 during Friday's pre-market session. The market value of their outstanding shares is at $63.4 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock rose 14.23% to $0.25. The market value of their outstanding shares is at $5.9 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) shares moved upwards by 12.42% to $1.9. The company's market cap stands at $275.8 million. </li>
<li>Allakos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALLK#NASDAQ">ALLK</a>) shares increased by 12.38% to $0.75. The company's market cap stands at $66.9 million. </li>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) stock increased by 11.41% to $1.25. The market value of their outstanding shares is at $1.9 million. </li>
<li>aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) stock moved upwards by 9.19% to $1.9. The company's market cap stands at $144.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock declined by 17.1% to $1.07 during Friday's pre-market session. The market value of their outstanding shares is at $2.3 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) shares fell 12.49% to $0.44. The market value of their outstanding shares is at $67.6 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) stock decreased by 11.28% to $6.2. The company's market cap stands at $378.6 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares decreased by 10.3% to $0.61. The market value of their outstanding shares is at $3.5 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock decreased by 7.86% to $4.66. The market value of their outstanding shares is at $2.3 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares declined by 7.83% to $2.59. The company's market cap stands at $9.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALLK

ATYR

AVGR

BCDA

BDSX

CHRO

MURA

RENB

RSLS

WORX

12 Health Care Stocks Moving In Friday's Pre-Market Session

On Thursday, Sage Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) announced that Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) had terminated its rights under the collaboration and license agreement with Sage, which was specific to the <a href="https://www.benzinga.com/pressreleases/24/09/b41042766/sage-therapeutics-announces-discontinuation-of-the-collaboration-with-biogen-on-the-sage-324-progr" target="_blank" rel="noreferrer noopener">SAGE-324 program</a>.
The companies recently announced negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324 for the chronic treatment of essential tremor (ET) and discontinued further clinical development of SAGE-324 in ET.
Essential tremor is&nbsp;a neurological disorder that causes involuntary shaking or trembling in certain body parts.
In July, the companies announced results from the Phase 2 KINETIC 2 dose-range study of SAGE-324 (BIIB124) as a potential treatment for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/07/39935226/sage-biogen-shelve-development-of-nervous-system-disorder-drug-after-data-disappoints" rel="noreferrer noopener">essential tremor (ET)</a>.
The KINETIC 2 Study did not demonstrate a statistically significant dose-response relationship in change from baseline to Day 91 based on the primary endpoint, The Essential Tremor Rating Assessment Scale (TETRAS) Performance Subscale (PS) Item 4 (upper limb) total score.
TETRAS is used to quantify the severity of tremors and their impact on daily living activities.
Given these results, Sage and Biogen will close the ongoing open-label safety study of SAGE-324 in ET and do not plan to conduct further clinical development of SAGE-324 in ET.
Under the terms of the collaboration and license agreement, the termination will be effective on February 17, 2025, and Sage will resume full ownership of the SAGE-324 asset.
Sage plans to continue to evaluate other potential indications, if any, for SAGE-324.
Sage and Biogen will continue to partner on Zurzuvae (zuranolone), the first and only FDA-approved oral treatment for women with postpartum depression.
Price Action: At the last check on Thursday, SAGE stock was up 1.42% at $7.12, and BIIB stock was up 1.77% at $192.42.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/09/41046115/why-is-pasithea-therapeutics-stock-surging-on-thursday" target="_blank" rel="noreferrer noopener">Why Is Pasithea Therapeutics Stock Surging On Thursday?</a></li>
</ul>

The companies recently announced negative results from the Phase 2 KINETIC 2 Study of investigational SAGE-324 for the chronic treatment of essential tremor (ET) and discontinued further clinical development of SAGE-324 in ET.&nbsp;

Sage Therapeutics Announced That Biogen Has Terminated Its Rights Under The Collaboration And License Agreement With Sage Specific To The SAGE-324 Program

Offerings

Sage Therapeutics Filed For Mixed Shelf; Size Not Disclosed

Truist Securities analyst Joon Lee maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold and lowers the price target from $18 to $13.

Truist Securities Maintains Hold on Sage Therapeutics, Lowers Price Target to $13

JP Morgan analyst Anupam Rama maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $12 to $10.

JP Morgan Maintains Neutral on Sage Therapeutics, Lowers Price Target to $10

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and maintains $25 price target.

Reiteration

HC Wainwright & Co. Reiterates Neutral on Sage Therapeutics, Maintains $25 Price Target

Sage Therapeutics shares are trading lower after the company reported worse-than-expected Q2 financial results. Also, Piper Sandler lowered its price target on the stock from$70 to $52.

Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Hold.

Needham Reiterates Hold on Sage Therapeutics

FINANCIAL GUIDANCE
<ul>
<li>Based upon the Company's current operating plan, Sage anticipates that its existing cash, cash equivalents and marketable securities, anticipated funding from ongoing collaborations, and estimated revenues, will support its operations into 2026.​</li>
<li>The Company does not anticipate receipt of any milestone payments from collaborations in the remainder of 2024.</li>
<li>The Company anticipates operating expenses will decrease in 2024 relative to 2023.​
<ul>
<li>With the availability of ZURZUVAE as an additional treatment for women with PPD, the Company anticipates ZULRESSO revenues will continue to decrease over time.</li>
</ul>
</li>
</ul>

Guidance

Sage Anticipates That Its Existing Cash, Cash Equivalents And Marketable Securities, Anticipated Funding From Ongoing Collaborations, And Estimated Revenues, Will Support Its Operations Into 2026

Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) reported quarterly losses of $(1.70) per share which missed the analyst consensus estimate of $(1.66) by 2.41 percent. This is a 36.57 percent increase over losses of $(2.68) per share from the same period last year. The company reported quarterly sales of $8.65 million which missed the analyst consensus estimate of $8.85 million by 2.19 percent. This is a 249.80 percent increase over sales of $2.47 million the same period last year.

Earnings Misses

Sage Therapeutics Q2 EPS $(1.70) Misses $(1.66) Estimate, Sales $8.65M Miss $8.85M Estimate

Providing a diverse range of perspectives from bullish to bearish, 14 analysts have published ratings on Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $16.64, with a high estimate of $25.00 and a low estimate of $8.00. This current average has decreased by 18.83% from the previous average price target of $20.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1722348083_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The analysis of recent analyst actions sheds light on the perception of Sage Therapeutics by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ritu Baral</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Hold</td>
<td>$10.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Outperform</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$16.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$18.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$28.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Sell</td>
<td>$8.00</td>
<td>-</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Announces</td>
<td>Neutral</td>
<td>$15.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Sage Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sage Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Sage Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Sage Therapeutics's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/SAGE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Sage Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Sage Therapeutics: A Closer Look</h2>
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
<h3>Sage Therapeutics's Economic Impact: An Analysis</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Sage Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately 139.89%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Sage Therapeutics's net margin excels beyond industry benchmarks, reaching -1372.86%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -14.41%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Sage Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -13.15%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Sage Therapeutics's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Sage Therapeutics Through The Eyes Of 14 Analysts

TD Cowen analyst Ritu Baral downgrades Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Buy to Hold and lowers the price target from $16 to $10.

TD Cowen Downgrades Sage Therapeutics to Hold, Lowers Price Target to $10

Goldman Sachs analyst Salveen Richter maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Neutral and lowers the price target from $19 to $11.

Goldman Sachs Maintains Neutral on Sage Therapeutics, Lowers Price Target to $11

Scotiabank analyst George Farmer maintains Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) with a Sector Outperform and lowers the price target from $19 to $17.

Scotiabank Maintains Sector Outperform on Sage Therapeutics, Lowers Price Target to $17

JP Morgan analyst Anupam Rama downgrades Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) from Overweight to Neutral and lowers the price target from $18 to $12.

JP Morgan Downgrades Sage Therapeutics to Neutral, Lowers Price Target to $12

Robert W. Baird analyst Joel Beatty has maintained their neutral stance on SAGE stock, giving a Hold rating on August 2. Joel Beatty has given his ...

SAGE Therapeutics Hold Rating Justified by Modest Zurzuvae Sales Growth and High Risk Clinical Prospects

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC – Research Report), Applied Therapeutics (APLT – Re...

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Applied Therapeutics (APLT) and SAGE Therapeutics (SAGE)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Teladoc (TDOC – Research Report), SAGE Therapeutics (SAGE – Resea...

Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), SAGE Therapeutics (SAGE) and Agios Pharma (AGIO)

In a report released today, Joon Lee from Truist Financial maintained a Hold rating on SAGE Therapeutics (SAGE – Research Report), with a price tar...

SAGE Therapeutics (SAGE) Gets a Hold from Truist Financial

THE LAWSUIT: A class action securities lawsuit was filed against Sage Therapeutics, Inc. (SAGE) that seeks to recover losses of Sage Therapeutics s...

Sage Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky LLP for More Information – SAGE

Sage Therapeutics files for $250M of common stock

Sage Therapeutics files prospectus to offer $250M of common stock

Biogen to end Sage deal for neuro candidate

SAGE Therapeutics ( ($SAGE) ) has shared an announcement. Biogen has informed Sage Therapeutics of its decision to terminate their collaboration on...

SAGE Therapeutics' SAGE-324 Collaboration with Biogen Ends

Sage cut to underperform by RBC ahead of data readouts

AGIO

APLT

TDOC

Legal

Press Releases

Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seeking Recovery for Investors – Contact The Gross Law Firm

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)

Pomerantz Law Firm Investigates Claims  On Behalf of Investors of Sage Therapeutics, Inc. - SAGE

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE

SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit

ROSEN, LEADING INVESTOR COUNSEL, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE

SAGE REMINDER – Robbins LLP Urges SAGE Investors to Obtain Legal Counsel in Light of the Pending Lead Plaintiff Deadline

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Outset Medical, Starbucks, Endava, and Sage and Encourages Investors to Contact the Firm

ROSEN, A RANKED AND LEADING FIRM, Encourages Sage Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAGE

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Top Stock Ideas Sent Daily — Join and Gain Your Edge

Comments

Sage Therapeutics

Sage Therapeutics (SAGE) Forecast

Sage Therapeutics (NASDAQ:SAGE) Stock, Quote.Headers.trade-ideas